What's New
Alector Therapeutics Announced Results from their Phase 3 Clinical Trial evaluating Latozinemab
Alector Therapeutics announced results from their Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) for people with FTD caused by variants in the progranulin (GRN gene). See Alector’s press release…
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic
KING OF PRUSSIA, Pa., Oct. 21, 2025 — Biotechnology company Alector announced today that the drug, latozinemab, failed to meet the criteria for safety and efficacy in a Phase 3…
AFTD Webinar: Talking to Family About Genetic FTD Risk
When a family learns FTD is genetic, it’s important to find relatives and convey the potential risk to them, as well as raise awareness around the hope research progress offers…
New York State FTD Registry Bill Signed into Law
KING OF PRUSSIA, Pa., Oct. 20, 2025 — New York State Governor Kathy Hochul on Friday signed into law a bill creating the nation’s first state-level frontotemporal dementia (FTD) registry. The New…
Advancing Hope: AFTD Convenes 3rd Annual FTD Research Roundtable Meeting
AFTD’s 2025 FTD Research Roundtable, in-person meeting, was held September 15-17 in Arlington, Virginia. Approximately 100 scientific stakeholders from academia, the biopharmaceutical industry, government & regulatory representatives, nonprofit partners, persons…
Epilepsy More Common in FTD than Alzheimer’s, Study Finds
Epilepsy symptoms and the prescription of antiseizure medications are more common in FTD than Alzheimer’s disease, as reported in a study published in JAMA Neurology. The study sheds light on…
AFTD Webinar: The Lived Experience with FTD: The Road to an FTD Diagnosis
While awareness of FTD disorders is increasing, many people still face a lengthy and complicated path to receiving a diagnosis. In this webinar, presenters will share their personal journeys…
Advancing Hope – AFTD Staff Attend 2025 ALS Nexus in Dallas
Amanda Gleixner, PhD, attended the Amyotrophic Lateral Sclerosis (ALS) Nexus, held in Dallas, TX in August. The ALS Nexus is an annual conference hosted by the ALS Association which brings…
The Lived Experience of FTD: The Benefits of Pets
The following Guest Feature was written by Deb Jobe, a member of the AFTD Persons With FTD Advisory Council. Deb was diagnosed with the corticobasal syndrome (CBS) subtype of FTD, and eventually…
Dr. Laura Podcast Hosts AFTD’s Esther Kane
AFTD Director of Support and Education Esther Kane, MSN, RN-CDP, joined Dr. Laura Schlesinger this week on her podcast, Dr. Laura’s Deep Dive. Kane provided context and background on FTD…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)